Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis.

ABSTRACT:

Background

The benefits and risks of off-label use of recombinant factor VIIa in patients without hemophilia are contested. We performed a systematic review to assess the effectiveness and safety of such use.

Methods

We searched electronic databases including MEDLINE, EMBASE and CENTRAL for randomized controlled trials comparing recombinant factor VIIa with placebo in any patient population except those with hemophilia up to January 2010. Eligible articles were assessed for inclusion, data were extracted, and study quality was evaluated. Outcomes included mortality, blood loss, requirements for red blood cell transfusion, number of patients transfused and thromboembolic events.

Results

We identified 26 trials: 14 on off-label prophylactic use of recombinant factor VII

SUBMITTER: Lin Y 

PROVIDER: S-EPMC3017272 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature